Clinical pharmacology of tolmesoxide in refractory heart failure
The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pul...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1981-01, Vol.21 (3), p.169-172 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 172 |
|---|---|
| container_issue | 3 |
| container_start_page | 169 |
| container_title | European journal of clinical pharmacology |
| container_volume | 21 |
| creator | O'Boyle, C P McGarry, K Fitzgerald, D Kelly, J G Horgan, J O'Malley, K |
| description | The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pulmonary artery diastolic pressure (PADP) were 1.7 +0.11/min/m2 and 30.5 +4.1 mm Hg respectively. The mean % rise in CI was 78.8 +23.3 and the mean % fall in PADP was 35.2 +5.2. The mean half life of tolmesoxide in these patients was markedly prolonged at 15.6 +6.6h. Side effects were minimal - vomiting was seen in 1 patient. This agent warrants further study in the long term management of refractory cardiac failure. |
| doi_str_mv | 10.1007/BF00627915 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73835258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73835258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-ab4f2a992f259b3d05480c0d05a2508149547c3ac82e44aa6c3e38f5149150ea3</originalsourceid><addsrcrecordid>eNpFkE1LAzEURYMotVY37oWsXAijL19NslOLVaHgRtfDa5rYkUxTkxmw_94Ri67u4h4ul0PIOYNrBqBv7ucAU64tUwdkzKTgFQPJDskYQLBqajUck5NSPgCYsiBGZKQFM0brMbmdxWbTOIx0u8bcoksxve9oCrRLsfUlfTUrT5sNzT5kdF3KO7r2mDsasIl99qfkKGAs_myfE_I2f3idPVWLl8fn2d2ictzwrsKlDByt5YEruxQrUNKAgyGRKzBMWiW1E-gM91IiTp3wwgQ1FEyBRzEhl7-725w-e1-6um2K8zHixqe-1FoYobgyA3j1C7qcShlu19vctJh3NYP6R1f9r2uAL_ar_bL1qz9070d8AwJZY88</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73835258</pqid></control><display><type>article</type><title>Clinical pharmacology of tolmesoxide in refractory heart failure</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>O'Boyle, C P ; McGarry, K ; Fitzgerald, D ; Kelly, J G ; Horgan, J ; O'Malley, K</creator><creatorcontrib>O'Boyle, C P ; McGarry, K ; Fitzgerald, D ; Kelly, J G ; Horgan, J ; O'Malley, K</creatorcontrib><description>The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pulmonary artery diastolic pressure (PADP) were 1.7 +0.11/min/m2 and 30.5 +4.1 mm Hg respectively. The mean % rise in CI was 78.8 +23.3 and the mean % fall in PADP was 35.2 +5.2. The mean half life of tolmesoxide in these patients was markedly prolonged at 15.6 +6.6h. Side effects were minimal - vomiting was seen in 1 patient. This agent warrants further study in the long term management of refractory cardiac failure.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00627915</identifier><identifier>PMID: 7318877</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Female ; Heart Failure - drug therapy ; Heart Failure - metabolism ; Heart Failure - physiopathology ; Hemodynamics - drug effects ; Humans ; Kinetics ; Male ; Middle Aged ; Sulfoxides - administration & dosage ; Sulfoxides - metabolism ; Sulfoxides - pharmacology ; Toluene - administration & dosage ; Toluene - analogs & derivatives ; Toluene - metabolism ; Toluene - pharmacology ; Vasodilator Agents - pharmacology</subject><ispartof>European journal of clinical pharmacology, 1981-01, Vol.21 (3), p.169-172</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-ab4f2a992f259b3d05480c0d05a2508149547c3ac82e44aa6c3e38f5149150ea3</citedby><cites>FETCH-LOGICAL-c282t-ab4f2a992f259b3d05480c0d05a2508149547c3ac82e44aa6c3e38f5149150ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7318877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Boyle, C P</creatorcontrib><creatorcontrib>McGarry, K</creatorcontrib><creatorcontrib>Fitzgerald, D</creatorcontrib><creatorcontrib>Kelly, J G</creatorcontrib><creatorcontrib>Horgan, J</creatorcontrib><creatorcontrib>O'Malley, K</creatorcontrib><title>Clinical pharmacology of tolmesoxide in refractory heart failure</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pulmonary artery diastolic pressure (PADP) were 1.7 +0.11/min/m2 and 30.5 +4.1 mm Hg respectively. The mean % rise in CI was 78.8 +23.3 and the mean % fall in PADP was 35.2 +5.2. The mean half life of tolmesoxide in these patients was markedly prolonged at 15.6 +6.6h. Side effects were minimal - vomiting was seen in 1 patient. This agent warrants further study in the long term management of refractory cardiac failure.</description><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - physiopathology</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Sulfoxides - administration & dosage</subject><subject>Sulfoxides - metabolism</subject><subject>Sulfoxides - pharmacology</subject><subject>Toluene - administration & dosage</subject><subject>Toluene - analogs & derivatives</subject><subject>Toluene - metabolism</subject><subject>Toluene - pharmacology</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEURYMotVY37oWsXAijL19NslOLVaHgRtfDa5rYkUxTkxmw_94Ri67u4h4ul0PIOYNrBqBv7ucAU64tUwdkzKTgFQPJDskYQLBqajUck5NSPgCYsiBGZKQFM0brMbmdxWbTOIx0u8bcoksxve9oCrRLsfUlfTUrT5sNzT5kdF3KO7r2mDsasIl99qfkKGAs_myfE_I2f3idPVWLl8fn2d2ictzwrsKlDByt5YEruxQrUNKAgyGRKzBMWiW1E-gM91IiTp3wwgQ1FEyBRzEhl7-725w-e1-6um2K8zHixqe-1FoYobgyA3j1C7qcShlu19vctJh3NYP6R1f9r2uAL_ar_bL1qz9070d8AwJZY88</recordid><startdate>19810101</startdate><enddate>19810101</enddate><creator>O'Boyle, C P</creator><creator>McGarry, K</creator><creator>Fitzgerald, D</creator><creator>Kelly, J G</creator><creator>Horgan, J</creator><creator>O'Malley, K</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19810101</creationdate><title>Clinical pharmacology of tolmesoxide in refractory heart failure</title><author>O'Boyle, C P ; McGarry, K ; Fitzgerald, D ; Kelly, J G ; Horgan, J ; O'Malley, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-ab4f2a992f259b3d05480c0d05a2508149547c3ac82e44aa6c3e38f5149150ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - physiopathology</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Sulfoxides - administration & dosage</topic><topic>Sulfoxides - metabolism</topic><topic>Sulfoxides - pharmacology</topic><topic>Toluene - administration & dosage</topic><topic>Toluene - analogs & derivatives</topic><topic>Toluene - metabolism</topic><topic>Toluene - pharmacology</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Boyle, C P</creatorcontrib><creatorcontrib>McGarry, K</creatorcontrib><creatorcontrib>Fitzgerald, D</creatorcontrib><creatorcontrib>Kelly, J G</creatorcontrib><creatorcontrib>Horgan, J</creatorcontrib><creatorcontrib>O'Malley, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Boyle, C P</au><au>McGarry, K</au><au>Fitzgerald, D</au><au>Kelly, J G</au><au>Horgan, J</au><au>O'Malley, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacology of tolmesoxide in refractory heart failure</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1981-01-01</date><risdate>1981</risdate><volume>21</volume><issue>3</issue><spage>169</spage><epage>172</epage><pages>169-172</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pulmonary artery diastolic pressure (PADP) were 1.7 +0.11/min/m2 and 30.5 +4.1 mm Hg respectively. The mean % rise in CI was 78.8 +23.3 and the mean % fall in PADP was 35.2 +5.2. The mean half life of tolmesoxide in these patients was markedly prolonged at 15.6 +6.6h. Side effects were minimal - vomiting was seen in 1 patient. This agent warrants further study in the long term management of refractory cardiac failure.</abstract><cop>Germany</cop><pmid>7318877</pmid><doi>10.1007/BF00627915</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1981-01, Vol.21 (3), p.169-172 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73835258 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Female Heart Failure - drug therapy Heart Failure - metabolism Heart Failure - physiopathology Hemodynamics - drug effects Humans Kinetics Male Middle Aged Sulfoxides - administration & dosage Sulfoxides - metabolism Sulfoxides - pharmacology Toluene - administration & dosage Toluene - analogs & derivatives Toluene - metabolism Toluene - pharmacology Vasodilator Agents - pharmacology |
| title | Clinical pharmacology of tolmesoxide in refractory heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A39%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacology%20of%20tolmesoxide%20in%20refractory%20heart%20failure&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=O'Boyle,%20C%20P&rft.date=1981-01-01&rft.volume=21&rft.issue=3&rft.spage=169&rft.epage=172&rft.pages=169-172&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00627915&rft_dat=%3Cproquest_cross%3E73835258%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73835258&rft_id=info:pmid/7318877&rfr_iscdi=true |